PAREXEL Introduces Biological Sample Lifecycle Management Service to Address Growing Demand Across Drug Development
Solution combines global laboratory logistics expertise with leading sample tracking software to optimize the management and care of human biological samples throughout their lifecycle
BOSTON, February 12, 2018 – PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, today launched its Biological Sample Lifecycle Management service, enabling optimal use of human biological samples. The new service enables biopharmaceutical clients to more efficiently manage their often irreplaceable patient biological sample assets from informed consent and collection at site, through in-study laboratory analysis, data generation and future use. The offering combines PAREXEL’s laboratory logistics and genomic medicine expertise with BioFortis consent and sample tracking software.
Human biological samples are essential to global drug development, particularly in areas such as personalized, precision and genomic medicine. PAREXEL’s new offering helps clients maintain sample integrity, security and compliance with changing regulations and guidelines. In addition, the service provides advanced oversight of samples across the complex ecosystem of laboratories, biorepositories and research and development facilities.
“Today, biopharmaceutical companies are experiencing an increased demand to provide full visibility into the chain of custody and consent status of human samples throughout the entire lifecycle, which involves complex logistics and data flows,” said Sanjay Vyas, Corporate Vice President and Global Head, Clinical Trial Supplies and Logistics, PAREXEL. “With this new offering, PAREXEL is leveraging its wide range of expertise to help clients optimize sample management to meet this demand and ultimately accelerate clinical development cycles so new medicines can reach patients sooner.”
The Biological Sample Lifecycle Management offering combines PAREXEL’s services with BioFortis’ Labmatrix™ software, a technology-enabled solution for clinical trial sample and consent tracking allowing study teams to monitor samples across a complex study ecosystem. The offering is the latest addition to PAREXEL’s Connected Journey™ of more than 40 data-driven services and is currently available worldwide. Demonstrations of the service will be provided at the BioFortis booth (#204) today through Thursday, February 15 during the 9th Annual SCOPE Summit for Clinical Ops Executives, taking place in Orlando, FL. For more information, please visit www.parexel.com/sample-management.
About PAREXEL International
PAREXEL International Corporation is the world’s leading innovator of biopharmaceutical services. We simplify our clients’ journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services. PAREXEL develops breakthrough innovations and solutions by leveraging its comprehensive therapeutic, technical and functional expertise, in more than 100 countries around the world. For more information visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
# # #
Tel.: +1 781-434-5104
Kathryn McMahon Arrigg, PAN Communications
Tel.: +1 617-502-4300